Becton, Dickinson and Company (NYSE:BDX) Shares Acquired by Victory Capital Management Inc.

Victory Capital Management Inc. increased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 4.6% in the fourth quarter, Holdings Channel reports. The firm owned 125,972 shares of the medical instruments supplier’s stock after acquiring an additional 5,519 shares during the period. Victory Capital Management Inc.’s holdings in Becton, Dickinson and Company were worth $30,716,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of BDX. Dover Advisors LLC increased its position in shares of Becton, Dickinson and Company by 1.7% in the third quarter. Dover Advisors LLC now owns 2,702 shares of the medical instruments supplier’s stock worth $699,000 after acquiring an additional 45 shares in the last quarter. Mendel Money Management raised its position in Becton, Dickinson and Company by 3.0% in the third quarter. Mendel Money Management now owns 1,536 shares of the medical instruments supplier’s stock valued at $397,000 after purchasing an additional 45 shares during the period. Phillips Wealth Planners LLC lifted its stake in shares of Becton, Dickinson and Company by 6.0% during the third quarter. Phillips Wealth Planners LLC now owns 818 shares of the medical instruments supplier’s stock worth $211,000 after purchasing an additional 46 shares in the last quarter. CWM LLC boosted its position in shares of Becton, Dickinson and Company by 0.7% in the fourth quarter. CWM LLC now owns 6,303 shares of the medical instruments supplier’s stock worth $1,537,000 after buying an additional 46 shares during the period. Finally, S.A. Mason LLC grew its position in Becton, Dickinson and Company by 3.5% in the fourth quarter. S.A. Mason LLC now owns 1,420 shares of the medical instruments supplier’s stock valued at $346,000 after acquiring an additional 48 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,715 shares of the stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total transaction of $399,269.15. Following the sale, the executive vice president now directly owns 5,381 shares in the company, valued at approximately $1,252,750.61. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 282 shares of the business’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $238.29, for a total transaction of $67,197.78. Following the completion of the transaction, the senior vice president now directly owns 2,276 shares of the company’s stock, valued at approximately $542,348.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael David Garrison sold 1,715 shares of the company’s stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total transaction of $399,269.15. Following the completion of the transaction, the executive vice president now owns 5,381 shares of the company’s stock, valued at approximately $1,252,750.61. The disclosure for this sale can be found here. 0.31% of the stock is currently owned by insiders.

Analyst Ratings Changes

Separately, Barclays raised their target price on Becton, Dickinson and Company from $305.00 to $312.00 and gave the company an “overweight” rating in a research note on Monday. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, Becton, Dickinson and Company presently has a consensus rating of “Moderate Buy” and a consensus price target of $281.40.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX opened at $237.14 on Wednesday. The company has a current ratio of 1.41, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $68.53 billion, a price-to-earnings ratio of 52.23, a price-to-earnings-growth ratio of 1.92 and a beta of 0.45. Becton, Dickinson and Company has a twelve month low of $229.40 and a twelve month high of $287.32. The business has a 50 day simple moving average of $238.27 and a 200-day simple moving average of $239.97.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share for the quarter, beating the consensus estimate of $2.97 by $0.20. Becton, Dickinson and Company had a net margin of 6.76% and a return on equity of 13.90%. The firm had revenue of $5.05 billion during the quarter, compared to analyst estimates of $5.04 billion. During the same quarter in the previous year, the firm earned $2.86 earnings per share. The firm’s revenue for the quarter was up 4.6% compared to the same quarter last year. As a group, equities research analysts expect that Becton, Dickinson and Company will post 13.04 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 28th. Shareholders of record on Monday, June 10th will be issued a $0.95 dividend. The ex-dividend date is Monday, June 10th. This represents a $3.80 dividend on an annualized basis and a yield of 1.60%. Becton, Dickinson and Company’s dividend payout ratio is currently 83.70%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.